A Study to Evaluate the Influence of Diet on GI Health

Overview

About this study

The purpose of this study is to understand the potential of protein and psyllium fiber to manipulate gut microbial densities, intestinal permeability, and inflammation in humans.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults ≥ 18 years old.
  • On a baseline diet characterized by:
    • Fiber intake of ≤ 20g/day;
    • > 18% of daily calories from protein.

Exclusion Criteria:

  • Individuals < 18 years old.
  • Prior history of gastrointestinal surgeries (except appendectomy and cholecystectomy).
  • Known diagnosis of inflammatory bowel disease (Crohn’s or ulcerative colitis), microscopic colitis, celiac disease, or other inflammatory GI condition.
  • Use of NSAIDs or aspirin and unable or unwilling to stop taking within the week prior to permeability test.
  • Use of osmotic laxatives and unable or unwilling to stop taking one week prior to permeability test and for the duration of the study.
  • Use of oral corticosteroids and unable or unwilling to stop use of oral corticosteroids within the previous 6 weeks and for the duration of the study.
  • Multiple dietary restrictions or unable/unwilling to alter dietary protein or dietary fiber.
  • Unwilling to stop ingestion of alcohol and artificial sweeteners such as Splenda™ (sucralose), Nutrasweet™ (aspartame), sorbitol, xylitol, lactulose, or mannitol 2 days before and during the permeability testing days; e.g., foods to be avoided are sugarless gums or mints and diet beverages.
  • Bowel preparation for colonoscopy less than one week prior to completion of the first stool kit and permeability test and flexible sigmoidoscopy and upper endoscopy.
  • Pregnancy or plan to become pregnant during the study time frame.
  • Known bleeding disorders or takes medications that increase risk of bleeding from mucosal biopsies.
  • Use of oral antibiotic(s) within the past 4 weeks (can be enrolled after 4-week washout period).
  • Use of commercial probiotic formulations and unwilling to stop for the duration of the study.
  • Diagnosis of diabetes.
  • Any other disease(s), condition(s) or habits(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.

Eligibility last updated 12/10/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Purna Kashyap, M.B.B.S.

Open for enrollment

Contact information:

Heather Lekatz CCRP, SOCRA

(507) 538-1206

Lekatz.Heather@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20515737

Mayo Clinic Footer